---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-006453"
form_type: "8-K"
ticker: "ENTA"
cik: "0001177648"
company_name: "ENANTA PHARMACEUTICALS INC"
filed_at: "2023-03-07T23:59:59+00:00"
generated_at: "2026-06-18T09:21:13.610430+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Enanta stockholders re-elect directors, approve equity plan amendment and say-on-pay

## Summary
- Re-elected Bruce L.A. Carter and Jay R. Luly as Class I directors with 14.3M and 16.7M votes for.
- Approved amendment to 2019 Equity Incentive Plan to increase authorized shares by 975,000.
- Advisory say-on-pay vote approved with 16.2M votes for versus 1.4M against.
- Ratified PricewaterhouseCoopers LLP as independent auditor for fiscal year 2023.

## SEC filing metadata
- accession: 0000950170-23-006453
- form_type: 8-K
- ticker: ENTA
- cik: 0001177648
- company_name: ENANTA PHARMACEUTICALS INC
- filed_at: 2023-03-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1177648/000095017023006453/0000950170-23-006453-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1177648/000095017023006453/enta-20230302.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-006453
- JSON: https://secwatch.observer/filing/0000950170-23-006453.json
- Plain text: https://secwatch.observer/filing/0000950170-23-006453.txt

## Key facts
- Shareholder Votes
  ENANTA PHARMACEUTICALS INC shareholders approved Advisory vote on executive compensation (say-on-pay) at the 2023-03-02 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-03-02
  source text: The stockholders approved the advisory vote on executive compensation, referred to as a "say-on-pay" vote.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1177648/000095017023006453/0000950170-23-006453-index.htm
- Shareholder Votes
  ENANTA PHARMACEUTICALS INC shareholders approved Election of Two Class I Directors at the 2023-03-02 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-03-02
  source text: The stockholders re-elected the following individuals as Class I directors of the Company: Name of Director Nominee Votes For Votes Withheld Broker Non-Votes Bruce L.A. Carter, Ph.D. 14,297,051 3,316,218 1,371,281 Jay R. Luly, Ph.D. 16,673,120 940,149 1,371,281
  evidence_url: https://www.sec.gov/Archives/edgar/data/1177648/000095017023006453/0000950170-23-006453-index.htm
- Shareholder Votes
  ENANTA PHARMACEUTICALS INC shareholders approved Approve an Amendment to Our 2019 Equity Incentive Plan to increase the number of shares reserved by 975,000 shares at the 2023-03-02 meeting.
  - Proposal: equity plan
  - Outcome: passed
  - Meeting: 2023-03-02
  source text: The stockholders approved the amendment to our 2019 Equity Incentive Plan to increase the number of shares of Common Stock reserved for issuance under the plan by 975,000 shares.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1177648/000095017023006453/0000950170-23-006453-index.htm
- Shareholder Votes
  ENANTA PHARMACEUTICALS INC shareholders approved Ratify the appointment of PricewaterhouseCoopers LLP as independent auditor for fiscal year 2023 at the 2023-03-02 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-03-02
  source text: The stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1177648/000095017023006453/0000950170-23-006453-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.